Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
Published online by Cambridge University Press: 09 February 2024
Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Summary
Which of the following represents the best and most evidence-based intervention for an adolescent with MDD who failed to respond to escitalopram (Lexapro) 20 mg daily for 4 months, and in whom escitalopram was discontinued 2 months ago?
- Type
- Chapter
- Information
- Case Studies: Stahl's Essential PsychopharmacologyChildren and Adolescents, pp. 49 - 64Publisher: Cambridge University PressPrint publication year: 2023
References
Asarnow, J. R., Emslie, G., Clarke, G., et al. Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response. J Am Acad Child Adolesc Psychiatry 2009; 48: 330–39. https://doi.org/10.1097/chi.0b013e3181977476Google Scholar
Bousman, C. A., Stevenson, J. M., Ramsey, L. B., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clin Pharmacol Ther 2023; 114: 51–68. https://doi.org/10.1002/cpt.2903Google Scholar
Compton, S. N., Peris, T. S., Almirall, D., et al. Predictors and moderators of treatment response in childhood anxiety disorders: results from the CAMS trial. J Consult Clin Psychol 2014; 82: 212–24. https://doi.org/10.1037/a0035458Google Scholar
Dobson, E. T., Bloch, M. H., Strawn, J. R. Efficacy and tolerability of pharmacotherapy in pediatric anxiety disorders: a network meta-analysis. J Clin Psychiatry 2019; 80: 17r12064. https://doi.org/10.4088/JCP.17r12064Google Scholar
Emslie, G. J., Prakash, A., Zhang, Q., et al. A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol 2014; 24: 170–79. https://doi.org/10.1089/cap.2013.0096Google Scholar
Greenblatt, D. J., Divoll Allen, M., Harmatz, J. S., Shader, R. I. Diazepam disposition determinants. Clin Pharmacol Ther 1980; 27: 301–12. https://doi.org/10.1038/clpt.1980.40Google Scholar
Gunlicks-Stoessel, M., Mufson, L., Bernstein, G., et al. Critical decision points for augmenting interpersonal psychotherapy for depressed adolescents: a pilot sequential multiple assignment randomized trial. J Am Acad Child Adolesc Psychiatry 2019; 58: 80–91. https://doi.org/10.1016/j.jaac.2018.06.032Google Scholar
Kneller, L. A., Zubiaur, P., Koller, D., Abad-Santos, F., Hempel, G. Influence of CYP2D6 phenotypes on the pharmacokinetics of aripiprazole and dehydro-aripiprazole using a physiologically based pharmacokinetic approach. Clin Pharmacokinet 2021; 60: 1569–82. https://doi.org/10.1007/s40262-021-01041-xGoogle Scholar
Locher, C., Koechlin, H., Zion, S. R., et al. Efficacy and safety of selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors, and placebo in common psychiatric disorders: a meta-analysis in children and adolescents. JAMA Psychiatry 2017; 74: 1011–20. https://doi.org/10.1001/jamapsychiatry.2017.2432Google Scholar
Shah, R. R., Smith, R. L. Addressing phenoconversion: the Achilles’ heel of personalized medicine. Br J Clin Pharmacol 2015; 79: 222–40. https://doi.org/10.1111/bcp.12441CrossRefGoogle ScholarPubMed
Shamseddeen, W., Clarke, G., Keller, M. B., et al. Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study. J Child Adolesc Psychopharmacol 2012; 22: 29–36. https://doi.org/10.1089/cap.2011.0027Google Scholar
Strawn, J. R., Prakash, A., Zhang, Q., et al. A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder. J Am Acad Child Adolesc Psychiatry 2015; 54: 283–93. https://doi.org/10.1016/j.jaac.2015.01.008Google Scholar
Strawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., Levine, A. Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother 2018a; 19: 1057–70. https://doi.org/10.1080/14656566.2018.1491966Google Scholar
Strawn, J. R., Mills, J. A., Sauley, B. A., Welge, J. A. The impact of antidepressant dose and class on treatment response in pediatric anxiety disorders: a meta-analysis. J Am Acad Child Adolesc Psychiatry 2018b; 57: 235–44.e2. https://doi.org/10.1016/j.jaac.2018.01.015Google Scholar
Strawn, J. R., Lu, L., Peris, T. S., Levine, A., Walkup, J. T. Research review: pediatric anxiety disorders – what have we learnt in the last 10 years? J Child Psychol Psychiatry 2021; 62: 114–39. https://doi.org/10.1111/jcpp.13262Google Scholar
Suresh, V., Mills, J. A., Croarkin, P. E., Strawn, J. R. What next? A Bayesian hierarchical modeling re-examination of treatments for adolescents with selective serotonin reuptake inhibitor-resistant depression. Depress Anxiety 2020; 37: 926–34. https://doi.org/10.1002/da.23064Google Scholar
Walkup, J. T., Albano, A. M., Piacentini, J., et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 2008; 359: 2753–66. https://doi.org/10.1056/NEJMoa0804633Google Scholar
Williams, T., Hattingh, C. J., Kariuki, C. M., et al. Pharmacotherapy for social anxiety disorder (SAnD). Cochrane Database Syst Rev 2017; 10: CD001206. https://doi.org/10.1002/14651858.CD001206.pub3Google Scholar
Zanger, U. M., Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138: 103–41. https://doi.org/10.1016/j.pharmthera.2012.12.007Google Scholar